One of our clients published preclinical data on NASH-fibrosis on PLoS One
We announced that a study in the STAM mouse model of NASH performed by SMC Laboratories Inc. has been published in PLoS One by Gemphire Therapeutics:
Title: “Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH”
The results of the study demonstrated Gemcabene in the STAM™ model showed a reduction in steatosis, NAFLD Activity score and fibrosis area.